AIM Rose 159% on Japan Patent Approval — RTPR Had the Wire in 92ms

AIM ImmunoTech (NASDAQ: AIM) gained 159% on March 18, 2026, after announcing Japan's final approval of a novel cancer therapy patent. RTPR subscribers saw the press release when the stock was trading at $0.70—the entry point available to anyone with access to the wire in real time.

What the Press Release Said

The GlobeNewswire announcement confirmed that Japan had granted final approval for AIM's patent combining Ampligen with checkpoint inhibitors for cancer treatment. Ampligen is the company's flagship immunomodulatory drug, and the patent covers a combination therapy approach that pairs it with existing checkpoint inhibitor drugs—a class that includes widely used cancer treatments.

Patent approvals in major markets like Japan represent meaningful intellectual property protection for biotech companies. For AIM, this milestone secures exclusivity for the Ampligen-checkpoint inhibitor combination in one of the world's largest pharmaceutical markets.

The Market Response

The stock moved from $0.70 at the time of the wire to a peak of $1.81 in the session—a 159% gain. Binary biotech catalysts tend to produce sharp, fast moves as traders price in new information. Patent approvals, while not as dramatic as FDA drug approvals, can still drive significant price action, particularly for small-cap names where the news materially changes the company's commercial outlook in a key geography.

For traders positioned at the $0.70 level when the wire hit, the move to $1.81 represented the kind of opportunity that hinges entirely on information speed.

RTPR Speed: The GlobeNewswire release reached RTPR subscribers in 92ms. At that moment, AIM was trading at $0.70. The stock reached a peak of $1.81 during the session. Free news aggregators typically lag wire services by 2–4 minutes—an eternity when a stock is repricing on a binary catalyst.

Why Speed Matters on Binary Catalysts

Patent approvals are scheduled events with known outcomes: approved or not approved. When the news drops, there's no ambiguity to parse. Traders who see the headline first can act while others are still waiting for aggregators, social media, or broker alerts to catch up.

The $0.70 entry point that existed when RTPR delivered the wire was available for a finite window. By the time the stock reached $1.81, anyone entering late was buying into strength rather than catching the initial move.

Want This Speed?

RTPR delivered this GlobeNewswire release in 92ms, when AIM was still at $0.70. See what real-time wire access costs at rtpr.io/pricing or review the API documentation at rtpr.io/docs.